Positron Emission Tomography (PET) Imaging of Thrombosis

Recruiting Phase 1 Interventional Study
Atrial Fibrillation COVID-19 Cancer Thrombosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 85
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Diagnostic
Participants needed
165 (estimated)
Sponsor
Massachusetts General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
For Atrial Fibrillation Patient subjects: * History of atrial fibrillation or paroxysmal atrial fibrillation; * Retrospective enrollment: TEE to evaluate LAA within the last 14 days, provided the anticoagulation regimen the patient is on is not changed after the TEE. If a patient has a negative TEE…
Contacts

David E Sosnovik, MD

617-724-3407

sosnovik@nmr.mgh.harvard.edu

CONTACT

Anne L Philip, MPH

617-726-0431

alphilip@mgh.harvard.edu

CONTACT